Sirukumab: Phase III data

Top-line data from the double-blind, international Phase III SIRROUND-D (CNTO136ARA3002) trial in 1,670 patients with moderately to severely active RA who had an inadequate response to DMARDs showed that subcutaneous 50 mg sirukumab every 4

Read the full 355 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE